Filing Flows › Medifast (MED) › Guidance & outlook

Medifast (MED) guidance and outlook

Medifast (MED) raised its guidance on Oct 26, 2026: Revenue $55.0M–$75.0M for Q4 2026; EPS $0.00–$0.25 for Q4 2026; Revenue $280M–$300M for FY2026; EPS $0.45–$0.70 for FY2026.

Guidance and outlook

Met or beat 2 of 2 guided periods. Grey: the last range guided before the figures came out; dot: the reported figure.

Latest guidance

Metric	Period	Range	Change
Revenue	Q4 2026	$55.0M–$75.0M	new
EPS	Q4 2026	$0.00–$0.25	new
Revenue	FY2026	$280M–$300M	raised
EPS	FY2026	$0.45–$0.70	new

From the earnings release filed Oct 26, 2026 (8-K on EDGAR).

Medifast's latest quarter

Medifast, Q3 2026: revenue $72.0M (-19% year over year), operating margin -26.9%, net loss $17.5M, operating cash flow $3.3M. The chart follows the revenue to costs, profit and cash.

Questions

Did Medifast raise or lower its guidance?

Medifast (MED) raised its guidance on Oct 26, 2026: Revenue $55.0M–$75.0M for Q4 2026; EPS $0.00–$0.25 for Q4 2026; Revenue $280M–$300M for FY2026; EPS $0.45–$0.70 for FY2026.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.